Rajan S. Patel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Rajan S. Patel has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
Kan Gao
Sydney Head and Neck Cancer Institute, Sydney Cancer Centre, Royal Prince Alfred Hospital and University of Sydney, Sydney, Australia
4 shared publicationsChristopher J. O'Brien
Sydney Head and Neck Cancer Institute, Sydney Cancer Centre, Royal Prince Alfred Hospital and University of Sydney, Sydney, Australia
3 shared publications- Jonathan Robert Clark
Department of Head and Neck Surgery Chris O'Brien Lifehouse Sydney New South Wales Australia
3 shared publications A Hong
Department of Radiation Oncology, Sydney Cancer Centre and University of Sydney, Sydney
2 shared publicationsB Rose
Sydney Head & Neck Cancer Institute, Sydney Cancer Centre, and University of Sydney, Gloucester House, Royal Prince Alfred Hospital, Camperdown
2 shared publications- Cheok Soon Lee
School of Medicine, Western Sydney University, Penrith, NSW 2751, Australia
2 shared publications
Latest Publications
- 18 July 2008
- Published by Wiley in Head & Neck
- Vol. 30 (9) , 1231-1236
Effectiveness of selective neck dissection in the treatment of the clinically positive neck
Background.: The aim of this work was to determine whether or not patients treated with therapeutic selective neck dissection for head and neck squamous cell carcinoma were oncologically disadvantaged compared with those having comprehensive procedures.Methods.: The study involves a retrospective review of 232 therapeutic neck dissections with a minimum of 2 years follow‐up.Results.: Patients having selective neck dissection had fewer adverse prognostic factors compared with patients having comprehensive dissection (pN2/3, p = .001; and extracapsular spread, p = .001). There were trends toward improved control in the dissected neck (96% vs 86%, p = .06), and disease‐specific survival (59% vs 43%, p = .06) following selective neck dissection. Disease‐specific survival for all patients was adversely affected by pN classification (p <.001) and extracapsular spread (p <.001).Conclusions.: Patients undergoing aggressive neck surgery had more extensive disease. Selective neck dissection can be used to effectively treat clinically positive nodal disease in selected patients. © 2008 Wiley Periodicals, Inc. Head Neck 2008
- 18 July 2008
- Published by Wiley in Head & Neck
- Vol. 30 (9) , 1231-1236
Effectiveness of selective neck dissection in the treatment of the clinically positive neck
Background.: The aim of this work was to determine whether or not patients treated with therapeutic selective neck dissection for head and neck squamous cell carcinoma were oncologically disadvantaged compared with those having comprehensive procedures.Methods.: The study involves a retrospective review of 232 therapeutic neck dissections with a minimum of 2 years follow‐up.Results.: Patients having selective neck dissection had fewer adverse prognostic factors compared with patients having comprehensive dissection (pN2/3, p = .001; and extracapsular spread, p = .001). There were trends toward improved control in the dissected neck (96% vs 86%, p = .06), and disease‐specific survival (59% vs 43%, p = .06) following selective neck dissection. Disease‐specific survival for all patients was adversely affected by pN classification (p <.001) and extracapsular spread (p <.001).Conclusions.: Patients undergoing aggressive neck surgery had more extensive disease. Selective neck dissection can be used to effectively treat clinically positive nodal disease in selected patients. © 2008 Wiley Periodicals, Inc. Head Neck 2008
- 1 May 2008
- Published by Wiley in The Laryngoscope
- Vol. 118 (5) , 780-785
The Prognostic Impact of Extent of Bone Invasion and Extent of Bone Resection in Oral Carcinoma
Objective: The prognostic impact of mandibular invasion by oral squamous cell carcinoma (SCC) is controversial. The objective of this study was to assess the effect that extent of bone invasion has on recurrence and survival in patients treated with marginal and segmental mandible resection.Study Design: A retrospective cohort study of patients whose clinicopathologic information had been collected prospectively into a dedicated head and neck database.Methods: Local control and disease‐specific survival were retrospectively reviewed in 111 patients (median follow‐up, 44 months) with oral SCC undergoing marginal or segmental mandibulectomy.Results: Bone invasion was present in 46% of marginal and 94% of segmental resections. Five‐year local control was similar following marginal (83%) and segmental mandibulectomy (86%). There was no correlation with presence or extent of bone invasion. Survival at 5 years was 71% and this correlated with bone invasion and involved margins (P < .05), but not with extent of mandible invasion or resection.Conclusions: Marginal mandibulectomy does not adversely alter outcome in selected patients with bone invasion provided margins are not compromised.
- 1 May 2008
- Published by Wiley in The Laryngoscope
- Vol. 118 (5) , 780-785
The Prognostic Impact of Extent of Bone Invasion and Extent of Bone Resection in Oral Carcinoma
Objective: The prognostic impact of mandibular invasion by oral squamous cell carcinoma (SCC) is controversial. The objective of this study was to assess the effect that extent of bone invasion has on recurrence and survival in patients treated with marginal and segmental mandible resection.Study Design: A retrospective cohort study of patients whose clinicopathologic information had been collected prospectively into a dedicated head and neck database.Methods: Local control and disease‐specific survival were retrospectively reviewed in 111 patients (median follow‐up, 44 months) with oral SCC undergoing marginal or segmental mandibulectomy.Results: Bone invasion was present in 46% of marginal and 94% of segmental resections. Five‐year local control was similar following marginal (83%) and segmental mandibulectomy (86%). There was no correlation with presence or extent of bone invasion. Survival at 5 years was 71% and this correlated with bone invasion and involved margins (P < .05), but not with extent of mandible invasion or resection.Conclusions: Marginal mandibulectomy does not adversely alter outcome in selected patients with bone invasion provided margins are not compromised.
- Open Access
- 1 December 2007
- Published by American Medical Association (AMA) in JAMA Otolaryngology–Head & Neck Surgery
- Vol. 133 (12) , 1282-1287
Squamous Cell Carcinoma From an Unknown Head and Neck Primary Site
Cervical lymph node metastasis from mucosal squamous cell carcinoma (SCC) is a relatively common head and neck presentation. However, approximately 5% of patients presenting with cervical lymph node metastasis of SCC have no identifiable primary site despite extensive diagnostic workup, including physical examination, fiberoptic endoscopy, examination with general anesthesia and targeted biopsies of potential primary sites, computed tomography or magnetic resonance imaging, and more recently fludeoxyglucose F18 positron emission tomography (PET).1,2
- 1 December 2007
- Published by American Medical Association (AMA) in JAMA Otolaryngology–Head & Neck Surgery
- Vol. 133 (12) , 1282-1287
Open AccessSquamous Cell Carcinoma From an Unknown Head and Neck Primary Site
Cervical lymph node metastasis from mucosal squamous cell carcinoma (SCC) is a relatively common head and neck presentation. However, approximately 5% of patients presenting with cervical lymph node metastasis of SCC have no identifiable primary site despite extensive diagnostic workup, including physical examination, fiberoptic endoscopy, examination with general anesthesia and targeted biopsies of potential primary sites, computed tomography or magnetic resonance imaging, and more recently fludeoxyglucose F18 positron emission tomography (PET).1,2
- 9 October 2007
- Published by Wiley in Histopathology
- Vol. 51 (5) , 691-696
Cyclin D1 and p16 expression in pleomorphic adenoma and carcinoma ex pleomorphic adenoma of the parotid gland
Aims: To compare cyclin D1 and p16ink4 (p16) expression in normal tissue, pleomorphic adenoma (PA) and carcinoma ex pleomorphic adenoma (CXPA) of the parotid gland.Methods and results: Immunohistochemistry was used to examine cyclin D1 and p16 expression in 43 parotid tumours (29 PAs and 14 CXPAs). Cyclin D1 and p16 were both significantly more likely to be expressed in the neoplastic than in the normal epithelial and stromal components of PA and CXPA (P < 0.001 and P < 0.005, respectively). Cyclin D1 was more likely to be expressed in the malignant components of CXPA than in the benign components of PA (50% versus 31% and 31%, respectively), but the trend was not statistically significant. There was no evidence of this association for p16 (corresponding positivity rates 69% versus 81% and 52%).Conclusions: Our findings provide preliminary evidence of roles for cyclin D1 and p16 in the development of PA and for cyclin D1 in the progression of PA to CXPA.
- 9 October 2007
- Published by Wiley in Histopathology
- Vol. 51 (5) , 691-696
Cyclin D1 and p16 expression in pleomorphic adenoma and carcinoma ex pleomorphic adenoma of the parotid gland
Aims: To compare cyclin D1 and p16ink4 (p16) expression in normal tissue, pleomorphic adenoma (PA) and carcinoma ex pleomorphic adenoma (CXPA) of the parotid gland.Methods and results: Immunohistochemistry was used to examine cyclin D1 and p16 expression in 43 parotid tumours (29 PAs and 14 CXPAs). Cyclin D1 and p16 were both significantly more likely to be expressed in the neoplastic than in the normal epithelial and stromal components of PA and CXPA (P < 0.001 and P < 0.005, respectively). Cyclin D1 was more likely to be expressed in the malignant components of CXPA than in the benign components of PA (50% versus 31% and 31%, respectively), but the trend was not statistically significant. There was no evidence of this association for p16 (corresponding positivity rates 69% versus 81% and 52%).Conclusions: Our findings provide preliminary evidence of roles for cyclin D1 and p16 in the development of PA and for cyclin D1 in the progression of PA to CXPA.
- 22 June 2007
- Published by Wiley in Histopathology
- Vol. 51 (1) , 21-25
Cyclin A expression and its diagnostic value in pleomorphic adenoma and carcinoma expleomorphic adenoma of the parotid gland
- 22 June 2007
- Published by Wiley in Histopathology
- Vol. 51 (1) , 21-25
Cyclin A expression and its diagnostic value in pleomorphic adenoma and carcinoma expleomorphic adenoma of the parotid gland
- 1 April 2007
- Published by Wiley in The Laryngoscope
- Vol. 117 (4) , 644-647
Clinical Outcome After Surgery for 75 Patients With Parotid Sialadenitis
Objective: To analyze the clinical outcome of patients treated surgically for chronic parotid sialadenitis.Study Design: A retrospective cohort study of patients whose clinicopathologic information had been collected prospectively onto a dedicated head and neck database.Methods: Between 1987 and 2006, a total of 75 patients had 78 parotidectomies, 17 superficial and 61 near‐total, to treat chronic parotid sialadenitis. The clinicopathologic data including treatment morbidity and outcome were analyzed.Results: Temporary postoperative facial weakness occurred in 26 (33%) patients, and this was permanent, although partial, in one (1%) patient. There was no significant difference (P > .05) in the incidence of temporary facial nerve neuropraxia in the superficial (35%) and near‐total parotidectomy (33%) groups. Recurrence of symptoms was noted in two patients who had undergone near‐total parotidectomy and none of the patients who had undergone superficial parotidectomy. Chronic parotid sialadenitis was effectively treated in 97% of patients undergoing parotidectomy.Conclusion: Near‐total parotidectomy is a safe and efficacious surgical treatment in the management of patients with debilitating severe chronic parotid sialadenitis.
- 1 April 2007
- Published by Wiley in The Laryngoscope
- Vol. 117 (4) , 644-647
Clinical Outcome After Surgery for 75 Patients With Parotid Sialadenitis
Objective: To analyze the clinical outcome of patients treated surgically for chronic parotid sialadenitis.Study Design: A retrospective cohort study of patients whose clinicopathologic information had been collected prospectively onto a dedicated head and neck database.Methods: Between 1987 and 2006, a total of 75 patients had 78 parotidectomies, 17 superficial and 61 near‐total, to treat chronic parotid sialadenitis. The clinicopathologic data including treatment morbidity and outcome were analyzed.Results: Temporary postoperative facial weakness occurred in 26 (33%) patients, and this was permanent, although partial, in one (1%) patient. There was no significant difference (P > .05) in the incidence of temporary facial nerve neuropraxia in the superficial (35%) and near‐total parotidectomy (33%) groups. Recurrence of symptoms was noted in two patients who had undergone near‐total parotidectomy and none of the patients who had undergone superficial parotidectomy. Chronic parotid sialadenitis was effectively treated in 97% of patients undergoing parotidectomy.Conclusion: Near‐total parotidectomy is a safe and efficacious surgical treatment in the management of patients with debilitating severe chronic parotid sialadenitis.
- 1 September 2004
- Published by SAGE Publications in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
- Vol. 41 (5) , 408-410
Morning salivary cortisol versus short Synacthen test as a test of adrenal suppression
Background: The short Synacthen test (SST) is the most commonly used test for the assessment of adrenal suppression. We investigated the potential of a simpler and more cost-effective procedure [morning salivary cortisol (MSC)] as an outpatient screening tool to detect adrenal suppression in patients using topical intranasal corticosteroids for rhinosinusitis. Method: Forty-eight patients who were using topical corticosteroids underwent adrenal function assessment by way of SST and MSC measurement. Results: Sixteen of the 48 patients had impaired MSCs. Of these 16 patients, 15 had an impaired SST (sensitivity 100%) and one had a normal SST. All patients with normal MSCs also had normal SSTs (specificity 97%). Conclusion: The morning salivary cortisol measurement is a useful screening tool for adrenal suppression in this setting.
- 1 September 2004
- Published by SAGE Publications in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
- Vol. 41 (5) , 408-410
Morning salivary cortisol versus short Synacthen test as a test of adrenal suppression
Background: The short Synacthen test (SST) is the most commonly used test for the assessment of adrenal suppression. We investigated the potential of a simpler and more cost-effective procedure [morning salivary cortisol (MSC)] as an outpatient screening tool to detect adrenal suppression in patients using topical intranasal corticosteroids for rhinosinusitis. Method: Forty-eight patients who were using topical corticosteroids underwent adrenal function assessment by way of SST and MSC measurement. Results: Sixteen of the 48 patients had impaired MSCs. Of these 16 patients, 15 had an impaired SST (sensitivity 100%) and one had a normal SST. All patients with normal MSCs also had normal SSTs (specificity 97%). Conclusion: The morning salivary cortisol measurement is a useful screening tool for adrenal suppression in this setting.
- 1 July 2004
- Published by Cambridge University Press (CUP) in The Journal of Laryngology & Otology
- Vol. 118 (7) , 528-531
Patient burden of centralization of head and neck cancer surgery
This study was undertaken to assess the impact on patients of proposals to centralize head and neck oncology services in the UK. A retrospective audit of the 2001–2002 head and neck cancer database at South Devon district general hospital identified 85 patients (50 males: 35 females; median age 66 years; range 29–93) diagnosed with head and neck cancer. The total number of hospital visits for diagnostic, therapeutic and other management services were recorded (median number of visits 28; range 1–78). Using this data, the extra distance required to travel to a potential regional cancer centre located in Bristol during the first six months of management was extrapolated. It was calculated that each patient would have to travel on average an extra 5333 miles (median 5658; range 185–13 759). Published documents advocating centralization of oncology services make no reference to the patient burden of geographic relocation of medical services. Agencies involved with restructuring oncology services must recognize the non-clinical impact of centralization and make some provision to overcome the burden facing patients and their carers.
- 1 July 2004
- Published by Cambridge University Press (CUP) in The Journal of Laryngology & Otology
- Vol. 118 (7) , 528-531
Patient burden of centralization of head and neck cancer surgery
This study was undertaken to assess the impact on patients of proposals to centralize head and neck oncology services in the UK. A retrospective audit of the 2001–2002 head and neck cancer database at South Devon district general hospital identified 85 patients (50 males: 35 females; median age 66 years; range 29–93) diagnosed with head and neck cancer. The total number of hospital visits for diagnostic, therapeutic and other management services were recorded (median number of visits 28; range 1–78). Using this data, the extra distance required to travel to a potential regional cancer centre located in Bristol during the first six months of management was extrapolated. It was calculated that each patient would have to travel on average an extra 5333 miles (median 5658; range 185–13 759). Published documents advocating centralization of oncology services make no reference to the patient burden of geographic relocation of medical services. Agencies involved with restructuring oncology services must recognize the non-clinical impact of centralization and make some provision to overcome the burden facing patients and their carers.
- 1 January 2004
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 42 (12)
Production of gender-specific morning salivary cortisol reference intervals using internationally accepted procedures
Background: Salivary cortisol concentrations correlate well with biologically active unbound free plasma cortisol concentrations. Despite its practical and analytical advantages, salivary cortisol measurement has been used mainly as a research tool rather than for the routine evaluation of adrenal function. This may be partly explained by the lack of robust reference data in the literature.Methods: Using the recommended procedures for the production of reference intervals published by the International Federation of Clinical Chemistry, we aimed to produce morning salivary cortisol reference intervals for males and females. Salivary cortisol was measured in 496 specimens collected from 248 reference individuals (128 males, median age 41years, range 16–86; and 120 females, median age 44years, range 16–98) attending an otorhinolaryngology clinic. Reference individuals mailed saliva specimens sampled on two consecutive mornings to our laboratory, where cortisol concentrations were measured.Results: Statistical analysis showed no significant correlation with age or body mass index. The following 95% gender-partitioned reference intervals were produced: males 10.9–40.3nmol/l; and females 9.3–40.3nmol/l.Conclusion: Knowledge of these salivary cortisol reference intervals helps us monitor the adrenal function of outpatients using topical intranasal glucocorticoids for rhinosinusitis.
- 1 January 2004
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 42 (12)
Production of gender-specific morning salivary cortisol reference intervals using internationally accepted procedures
Background: Salivary cortisol concentrations correlate well with biologically active unbound free plasma cortisol concentrations. Despite its practical and analytical advantages, salivary cortisol measurement has been used mainly as a research tool rather than for the routine evaluation of adrenal function. This may be partly explained by the lack of robust reference data in the literature.Methods: Using the recommended procedures for the production of reference intervals published by the International Federation of Clinical Chemistry, we aimed to produce morning salivary cortisol reference intervals for males and females. Salivary cortisol was measured in 496 specimens collected from 248 reference individuals (128 males, median age 41years, range 16–86; and 120 females, median age 44years, range 16–98) attending an otorhinolaryngology clinic. Reference individuals mailed saliva specimens sampled on two consecutive mornings to our laboratory, where cortisol concentrations were measured.Results: Statistical analysis showed no significant correlation with age or body mass index. The following 95% gender-partitioned reference intervals were produced: males 10.9–40.3nmol/l; and females 9.3–40.3nmol/l.Conclusion: Knowledge of these salivary cortisol reference intervals helps us monitor the adrenal function of outpatients using topical intranasal glucocorticoids for rhinosinusitis.
- 1 August 2001
- Published by Cambridge University Press (CUP) in The Journal of Laryngology & Otology
- Vol. 115 (8) , 633-635
Most patients overdose on topical nasal corticosteroid drops: an accurate delivery device is required
Otolaryngologists and general practitioners commonly prescribed intranasal corticosteroid drops for rhinitis. Compliance in real patients has not previously been studied, but is generally believed to be poor. Recent concerns over systemic adverse effects of topical corticosteroids have highlighted the risks of overdosing. Fifty patients, who were prescribed betamethasone, were prospectively studied for accuracy of compliance using a weighed dose study. Patients consistently administered inaccurate quantities of nasal corticosteroid drops, with a marked tendency to overdose up to four times the recommended daily dose (RDD) in some cases. The mean dose administered was 200 per cent of the RDD. Of the 50 patients, only seven (14 per cent) administered the correct dose. The introduction of metered-dose delivery systems should be considered to reduce the risk of inadvertent overdosing.
- 1 August 2001
- Published by Cambridge University Press (CUP) in The Journal of Laryngology & Otology
- Vol. 115 (8) , 633-635
Most patients overdose on topical nasal corticosteroid drops: an accurate delivery device is required
Otolaryngologists and general practitioners commonly prescribed intranasal corticosteroid drops for rhinitis. Compliance in real patients has not previously been studied, but is generally believed to be poor. Recent concerns over systemic adverse effects of topical corticosteroids have highlighted the risks of overdosing. Fifty patients, who were prescribed betamethasone, were prospectively studied for accuracy of compliance using a weighed dose study. Patients consistently administered inaccurate quantities of nasal corticosteroid drops, with a marked tendency to overdose up to four times the recommended daily dose (RDD) in some cases. The mean dose administered was 200 per cent of the RDD. Of the 50 patients, only seven (14 per cent) administered the correct dose. The introduction of metered-dose delivery systems should be considered to reduce the risk of inadvertent overdosing.